Biomarin Pharmaceutical Inc. Earnings

Biomarin Pharmaceutical Inc.’s revenue jumped 14.84% since last year same period to $745.15Mn in the Q1 2025. On a quarterly growth basis, Biomarin Pharmaceutical Inc. has generated 0.94% jump in its revenue since last 3-months.

Biomarin Pharmaceutical Inc.’s net profit jumped 109.43% since last year same period to $185.69Mn in the Q1 2025. On a quarterly growth basis, Biomarin Pharmaceutical Inc. has generated 48.62% jump in its net profits since last 3-months.

Biomarin Pharmaceutical Inc.’s net profit margin jumped 82.36% since last year same period to 24.92% in the Q1 2025. On a quarterly growth basis, Biomarin Pharmaceutical Inc. has generated 47.24% jump in its net profit margins since last 3-months.

Biomarin Pharmaceutical Inc.’s price-to-earnings ratio after this Q1 2025 earnings stands at 20.37.

Biomarin Pharmaceutical Inc.’s earning per share (EPS) estimates for the current quarter stand at 0.65 - a -11.77% fall from last quarter’s estimates.

Biomarin Pharmaceutical Inc.’s earning per share (EPS) estimates for the current year stand at 0.65.

Biomarin Pharmaceutical Inc.’s earning per share (EPS) jumped 145.65% since last year same period to 1.13 in the Q1 2025. This indicates that the Biomarin Pharmaceutical Inc. has generated 145.65% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Biomarin Pharmaceutical Inc.’s return on assets (ROA) stands at 0.06.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Biomarin Pharmaceutical Inc.’s return on equity (ROE) stands at 0.1.